Valeant Pharmaceuticals International CEO Joseph Papa's 2018 pay jumps 201% to $15M

Valeant Pharmaceuticals International reports 2018 executive compensation

By ExecPay News

Published: March 18, 2019

Valeant Pharmaceuticals International reported fiscal year 2018 executive compensation information on March 18, 2019.

In 2018, five executives at Valeant Pharmaceuticals International received on average a compensation package of $6.2M, a 39% increase compared to previous year.

Average pay of disclosed executives at Valeant Pharmaceuticals International

Joseph C. Papa, Chief Executive Officer, received $15M in total, which increased by 201% compared to 2017. 50% of Papa's compensation, or $7.3M, was in stock awards. Papa also received $3.8M in non-equity incentive plan, $2M in option awards, $1.5M in salary, as well as $94K in other compensation.

For fiscal year 2018, the median employee pay was $37,872 at Valeant Pharmaceuticals International. Therefore, the ratio of Joseph C. Papa's pay to the median employee pay was 389 to one.

Paul S. Herendeen, Chief Financial Officer, received a compensation package of $6.4M, which increased by 146% compared to previous year. 36% of the compensation package, or $2.3M, was in stock awards.

Thomas J. Appio, President & Co, Head, Bausch + Lomb/International, earned $4.4M in 2018, a 28% increase compared to previous year.

Christina M. Ackermann, General Counsel, received $3.4M in 2018, which increases by 21% compared to 2017.

Joseph F. Gordon, President & Co, Head, Bausch + Lomb/International, earned $2M in 2018.